Skip to main content

Table 2 Demographics of the 88 CMV seropositive (R+) lung transplant recipients

From: Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients

Characteristics Oral ganciclovir 3 months Valganciclovir 3 months
  (n = 37) (n = 51)
LTx, years 2001-2003 2004-2006
Recipient age years, mean (range) 49 (15-64) 52 (13-67)
    Female (%) 68 63
Donor age years, mean (range) 40 (11-61) 42 (5-70)
    Female (%) 51 57
    CMV + (%) 81 71
Tx type (%)   
-Single 78 71
-Double 19 29
-Heart and lung 3 0
Pre-transplant diagnosis (%)   
-COPD 41 37
-A1AT 24 16
-IPF 19 25
-CF 5 2
-PAH 3 6
-Eisenmenger syndrome 3 0
-Sarcoidosis 3 0
-GVHD 3 4
-Scleroderma 0 6
-Pulmonary embolism 0 4
  1. None of the differences were statistically significant.
  2. COPD = chronic obstructive pulmonary disease, CF = Cystic fibrosis, A1AT = alpha-1antitrypsin deficiency with emphysema, IPF = idiopathic pulmonary fibrosis, PAH = pulmonary arterial hypertension, GVHD = graft-versus-host disease.